An Oral

Yujun Liu, Hao Gong, Jiaming Zhu, Fenyong Liu

Abstract read

In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Developing Antiviral Vaccines Based on AttenuatedPathogens (Basel, Switzerland) · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yujun LiuSchool of Public Health, University of California, Berkeley, CA 94720, USA.

Hao GongProgram in Comparative Biochemistry, University of California, Berkeley, CA 94720, USA.

Jiaming ZhuProgram in Comparative Biochemistry, University of California, Berkeley, CA 94720, USA.

Fenyong LiuSchool of Public Health, University of California, Berkeley, CA 94720, USA.

Funding

University of California, Berkeley Start Up Fund 101

6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is the leading viral cause of congenital infections and causes substantial morbidity and mortality in neonates and immunosuppressed people. Generating an anti-HCMV vaccine is required for preventing viral-associated diseases and infections. Oral vaccines based on attenuated

Indexed as

Herpesviridae InfectionsMuromegalovirusSalmonellaViral ProteinsViral VaccinesAdministration, OralAnimalsAntibodies, ViralFemaleImmunoglobulin GMiceMice, Inbred BALB CT-LymphocytesVaccines, AttenuatedAntibodies, ViralImmunoglobulin GVaccines, AttenuatedViral ProteinsViral Vaccinescytomegalovirusherpesvirushuman cytomegalovirusimmune responsemurine cytomegalovirusoral vaccineSalmonella

Identifiers

PMID41011802

DOI10.3390/pathogens14090902

PMCPMC12472285

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.